The second factor was VEGF, the discovery of which also proved to be a scientific and therapeutic breakthrough, as it marked the beginning of a new era in anti-angiogenic therapy of solid tumours in humans (including HCC) [2,5,6,7]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.